Pancreatic Cancer Research

ResearcherKeio UniversityActive in the last 2 years

Yuko Kitagawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0271-5670; OpenAlex author ID A5101521231. Sources: OpenAlex.

Their work

Papers
37 (first author 0, last author 26)
Trials
0
Grants
0
Labs led
1
Collaborators
72
Papers, trials and grants by year

2013: 2 papers · 2014: 3 papers · 2015: 3 papers · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 3 papers · 2020: 3 papers · 2021: 4 papers · 2022: none · 2023: 1 paper · 2024: 6 papers · 2025: 4 papers · 2026: 3 papers

Papers 37

  1. Impact of Sarcopenia During Induction Treatment in Patients With Unresectable Locally Advanced Pancreatic Cancer. Last author DOI 10.1002/ags3.70078↗
  2. Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00535-026-02343-2↗
  3. A Pancreatic Ductal Adenocarcinoma Diagnostic System Using Serum Extracellular Vesicle Detection with Optimized Lectin Combination Using Machine Learning. Co-author DOI 10.3390/cancers18060924↗
  4. ASO Author Reflections: Indication Criteria for Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-025-16980-z↗
  5. Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Cancer (TOSPAC-02): A Phase 2 Clinical Tria… Last author DOI 10.1245/s10434-025-17661-7↗
  6. ASO Author Reflections: Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Cancer (TOSPAC-02)-… Last author DOI 10.1245/s10434-025-17876-8↗
  7. Pancreatic Cancer in Hereditary Breast and Ovarian Cancer Syndrome: Is Early Detection Possible? Last author DOI 10.2302/kjm.2024-0018-oa↗
  8. Impact of the COVID-19 pandemic on short-term outcomes after pancreaticoduodenectomy for pancreatic cancer: A retrospective study from the Japanese National Cl… Last author DOI 10.1002/ags3.12798↗
  9. Wnt-deficient and hypoxic environment orchestrates squamous reprogramming of human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41556-024-01498-5↗
  10. Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-024-72569-8↗
  11. Efficacy and safety of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer Last author DOI 10.21203/rs.3.rs-4671932/v1↗
  12. Evidence and Future Perspectives for Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Scoping Review. Last author DOI 10.3390/cancers16091632↗
  13. Next‑generation sequencing to identify genetic mutations in pancreatic cancer using intraoperative peritoneal washing fluid. Last author DOI 10.3892/ol.2024.14272↗
  14. Long-term survival after surgical resection for bone metastasis from pancreatic cancer: A case report. Last author DOI 10.1097/md.0000000000035856↗
  15. Clinicopathological impacts of DNA methylation alterations on pancreatic ductal adenocarcinoma: prediction of early recurrence based on genome-wide DNA methyla… Co-author DOI 10.1007/s00432-021-03541-6↗
  16. Hereditary pancreatic cancer. Co-author DOI 10.1007/s10147-021-02015-6↗
  17. Familial pancreatic cancer with PALB2 and NBN pathogenic variants: a case report. Co-author DOI 10.1186/s13053-020-00160-z↗
  18. Peritoneal dissemination of pancreatic cancer caused by endoscopic ultrasound-guided fine needle aspiration: A case report and literature review. Last author DOI 10.3748/wjg.v27.i3.294↗
  19. Usefulness of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant thera… Last author DOI 10.1002/cam4.3044↗
  20. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer. Last author DOI 10.1111/cas.14425↗
  21. O-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer. Last author DOI 10.3390/cancers12092469↗
  22. Characterization of spatial distribution of tumor-infiltrating CD8+ T cells refines their prognostic utility for pancreatic cancer survival. Co-author DOI 10.1038/s41379-019-0291-z↗
  23. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline rese… Last author DOI 10.1186/s12957-019-1687-4↗
  24. Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma. Last author DOI 10.3892/mco.2019.1883↗
  25. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study. Last author DOI 10.1038/bjc.2017.479↗
  26. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study. Last author DOI 10.1002/cam4.1178↗
  27. Corrigendum to "Beneficial effects of 5-fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin C and cisplatin after curative rese… Last author DOI 10.1016/j.pan.2016.12.014↗
  28. Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00428-016-2026-6↗
  29. Two cases of pancreatic ductal adenocarcinoma with intrapancreatic metastasis. Last author DOI 10.3748/wjg.v22.i41.9222↗
  30. Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/labinvest.2014.166↗
  31. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Last author DOI 10.1111/cas.12621↗
  32. Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer. Last author DOI 10.2302/kjm.2014-0014-cr↗
  33. Computer assisted surgery, preoperative planning and navigation for pancreatic cancer. Last author DOI 10.1002/jhbp.84↗
  34. Presence of primary cilia in cancer cells correlates with prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2013.11.017↗
  35. Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/labinvest.2014.53↗
  36. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer. Last author DOI 10.1007/s10585-012-9544-7↗
  37. Mesenchymal stem cells regulate epithelial-mesenchymal transition and tumor progression of pancreatic cancer cells. Co-author DOI 10.1111/cas.12059↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoru Kitago · 31 shared papers, 2014–2026 · strength 4.83
  2. Yuta Abe · 18 shared papers, 2014–2026 · strength 2.34
  3. Yutaka Nakano · 15 shared papers, 2017–2026 · strength 2.29
  4. Shutaro Hori · 12 shared papers, 2016–2026 · strength 1.81
  5. Yutaka Endo · 10 shared papers, 2018–2025 · strength 1.64
  6. Yohei Masugi · 16 shared papers, 2013–2026 · strength 1.60
  7. Masayuki Tanaka · 6 shared papers, 2021–2026 · strength 1.15
  8. Gaku Shimane · 4 shared papers, 2024–2026 · strength 1.05
  9. Sho Uemura · 4 shared papers, 2024–2026 · strength 1.00
  10. Kodai Abe · 4 shared papers, 2020–2025 · strength 0.65
  11. Koichi Aiura · 8 shared papers, 2013–2025 · strength 0.61
  12. Michiie Sakamoto · 9 shared papers, 2013–2021 · strength 0.53
  13. Yosuke Uematsu · 2 shared papers, 2025–2026 · strength 0.48
  14. Hiroshi Nishihara · 2 shared papers, 2024 · strength 0.37
  15. Akira Hirasawa · 2 shared papers, 2021 · strength 0.32
  16. Junichi Matsui · 2 shared papers, 2017–2025 · strength 0.31
  17. Ayumi Kashiro · 2 shared papers, 2020–2026 · strength 0.31
  18. Atsushi Kuno · 2 shared papers, 2020–2026 · strength 0.31
  19. Yasuaki Kabe · 2 shared papers, 2020–2026 · strength 0.31
  20. Kazufumi Honda · 2 shared papers, 2020–2026 · strength 0.31
  21. Yusuke Takemura · 2 shared papers, 2021–2024 · strength 0.29
  22. Eisuke Iwasaki · 2 shared papers, 2021–2024 · strength 0.26
  23. Yoko Fujii‐Nishimura · 4 shared papers, 2015–2019 · strength 0.26
  24. Takahiro Yokose · 3 shared papers, 2020 · strength 0.25
  25. Mutsuo Furihata · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.